'מערכת אימד'Buisson A et.al.; Aliment Pharmacol Ther. 2024 Feb;59(4):526-534
Abstract
Background: The long-term risk of relapse after switching from intravenous (IV) to subcutaneous (SC) infliximab remains unknown in inflammatory bowel disease (IBD).
Buisson A, Nachury M, Bazoge M, Yzet C, Wils P, Dodel M, Coban D, Pereira B, Fumery M. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study. Aliment Pharmacol Ther. 2024 Feb;59(4):526-534. doi: 10.1111/apt.17822. Epub 2023 Nov 30. PMID: 38037279.